Gossamer Bio, Inc. (GOSS)
NASDAQ$1.39
Market Cap
$314.98M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
206 of 924
Rank in Industry
121 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GOSS Insider Trading Activity
GOSS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $324,442 | 3 | 33 |
Sells | $53,578 | 6 | 67 |
Related Transactions
| Hasnain Faheem | President & CEO | 1 | $250,282 | 1 | $26,773 | $223,509 |
| Giraudo Bryan | COO/CFO | 1 | $59,110 | 1 | $7,431 | $51,679 |
| Smith Robert Paul JR | Chief Commercial Officer | 1 | $15,050 | 0 | $0 | $15,050 |
| Peterson Caryn | EVP, Regulatory Affairs | 0 | $0 | 1 | $5,343 | $-5,343 |
| Aranda Richard | Chief Medical Officer | 0 | $0 | 2 | $6,602 | $-6,602 |
| Christian Waage | EVP, Tech Ops and Admin | 0 | $0 | 1 | $7,430 | $-7,430 |
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel …
Insider Activity of Gossamer Bio, Inc.
Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $53,578 worth of Gossamer Bio, Inc. stock.
On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $287,158 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $250,282. Giraudo Bryan (COO/CFO) — $59,110. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.
The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.
| 2024-06-24 | Sale | Aranda Richard | Chief Medical Officer | 1,908 0.0007% | $0.66 | $1,260 | +12.58% | |
| 2024-06-21 | Hasnain Faheem | President & CEO | 372,000 0.2168% | $0.67 | $250,282 | +43.08% | ||
| 2024-06-18 | Giraudo Bryan | COO/CFO | 100,000 0.0512% | $0.59 | $59,110 | +71.46% | ||
| 2024-06-17 | Smith Robert Paul JR | Chief Commercial Officer | 25,000 0.013% | $0.60 | $15,050 | +78.77% | ||
| 2024-03-27 | Sale | Christian Waage | EVP, Tech Ops and Admin | 6,430 0.0028% | $1.16 | $7,430 | -22.28% | |
| 2024-03-27 | Sale | Hasnain Faheem | President & CEO | 23,172 0.0101% | $1.16 | $26,773 | -22.28% | |
| 2024-03-27 | Sale | Giraudo Bryan | COO/CFO | 6,430 0.0028% | $1.16 | $7,431 | -22.28% | |
| 2024-03-18 | Sale | Aranda Richard | Chief Medical Officer | 4,018 0.0017% | $1.33 | $5,342 | -33.98% | |
| 2024-03-18 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,018 0.0017% | $1.33 | $5,343 | -33.98% | |
| 2023-11-15 | Milligan Sandra | director | 32,000 0.0139% | $0.79 | $25,213 | +11.07% | ||
| 2023-11-13 | Giraudo Bryan | COO/CFO | 200,000 0.0795% | $0.56 | $112,880 | +43.00% | ||
| 2023-06-22 | Sale | Aranda Richard | Chief Medical Officer | 1,814 0.0018% | $1.29 | $2,340 | -34.61% | |
| 2023-04-04 | Giraudo Bryan | COO/CFO | 55,000 0.0583% | $1.02 | $56,095 | +3.96% | ||
| 2023-03-16 | Sale | Aranda Richard | Chief Medical Officer | 7,563 0.0083% | $1.10 | $8,304 | 0.00% | |
| 2023-03-16 | Sale | Carter Laura | Chief Scientific Officer | 6,029 0.0066% | $1.10 | $6,620 | 0.00% | |
| 2023-03-16 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 7,564 0.0083% | $1.10 | $8,305 | 0.00% | |
| 2022-10-24 | Sale | Aranda Richard | Chief Medical Officer | 4,757 0.0056% | $12.07 | $57,431 | -88.98% | |
| 2022-10-24 | Sale | Carter Laura | Chief Scientific Officer | 4,876 0.0058% | $12.07 | $58,868 | -88.98% | |
| 2022-10-24 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,757 0.0056% | $12.07 | $57,431 | -88.98% | |
| 2022-07-15 | Hasnain Faheem | President & CEO | 138,696 0.099% | $7.21 | $999,998 | -79.92% |
Total: 62
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Hasnain Faheem | President & CEO | 5408073 2.3866% | $7.52M | 4 | 2 | <0.0001% |
| Christian Waage | EVP, Tech Ops and Admin | 585934 0.2586% | $814,448.26 | 4 | 3 | <0.0001% |
| Giraudo Bryan | COO/CFO | 480010 0.2118% | $667,213.90 | 9 | 3 | +0.58% |
| Smith Robert Paul JR | Chief Commercial Officer | 25000 0.011% | $34,750.00 | 1 | 0 | |
| Gujrathi Sheila | President & CEO | 4048242 1.7865% | $5.63M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$99,438,720 | 81 | 6.74% | $303.29M | |
$5,911,307 | 70 | -1.38% | $321.78M | |
$109,415,500 | 33 | 18.13% | $364.07M | |
$41,446,394 | 27 | 12.91% | $324.97M | |
$24,857,912 | 21 | -35.40% | $283.23M |
GOSS Institutional Investors: Active Positions
| Increased Positions | 49 | +44.95% | 23M | +13.38% |
| Decreased Positions | 40 | -36.7% | 27M | -15.41% |
| New Positions | 18 | New | 2M | New |
| Sold Out Positions | 13 | Sold Out | 6M | Sold Out |
| Total Postitions | 118 | +8.26% | 171M | -2.02% |
GOSS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Octagon Capital Advisors Lp | $26,608.00 | 8.08% | 18.35M | +9M | +99.72% | 2024-12-31 |
| Nea Management Company, Llc | $26,235.00 | 7.97% | 18.09M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $14,550.00 | 4.42% | 10.03M | -2M | -14.63% | 2024-12-31 |
| Alyeska Investment Group, L.P. | $12,772.00 | 3.88% | 8.81M | +3M | +52.73% | 2024-12-31 |
| Arch Venture Management, Llc | $11,681.00 | 3.55% | 8.06M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $11,503.00 | 3.5% | 7.93M | -2,735 | -0.03% | 2024-12-31 |
| 683 Capital Management, Llc | $10,114.00 | 3.07% | 6.97M | +1M | +20.26% | 2024-12-31 |
| Palo Alto Investors Lp | $9,102.00 | 2.77% | 6.28M | 0 | 0% | 2024-12-31 |
| Silverarc Capital Management, Llc | $8,949.00 | 2.72% | 6.17M | +526,495 | +9.33% | 2024-12-31 |
| Samsara Biocapital, Llc | $8,889.00 | 2.7% | 6.13M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.